Liver stiffness in the hepatitis B virus carrier: A non-invasive marker of liver disease influenced by the pattern of transaminases

Figure 1 Distribution of Fibroscan values in Blood donors (Controls), Inactive carriers without (True I. C.) or with dysmetabolic liver disease (I.C. with LD) and in CHB patients by fibrosis stage (S0-S2, S3-S4, S5-S6, US Cirrhosis).

Figure 2 FS diagnostic performance: AUROCs for fibrosis S3 and cirrhosis were 0. 966 and 0.973 (95% CI 0.942-0.989 and 0.952-0.994).

Figure 3 FS and ALT kinetics in four patients. A: CHB with S2 fibrosis stage and recurrent hepatitis flare; B: Acute hepatitis B; C: CHB with S6 fibrosis stage responding to IFN treatment; D: Cirrhosis with biochemical break-through due to lamivudine resistance and response to rescue therapy with adefovir.